Price$0.67+0.01 (+1.70%)
01:30 PM07:45 PM
News · 26 weeks30-37%
2025-12-072026-05-31
Mix2090d
- SEC Filings11(55%)
- Other9(45%)
Latest news
25 items- PRGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific SessionsRUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that company leadership will present on its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association's (ADA) 2026 Scientific Sessions, taking place in New Orleans, June 5 – 8, 2026. As part of the ADA's Innovation Hub, Mark Tapsak, PhD, Glucotrack's Chief Scientific Officer, will present on the potential of next-generation CGM technology that addresses unmet patient needs thro
- SECGlucoTrack Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form 10-Q filed by GlucoTrack Inc.10-Q - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsSubmitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology Company targeting U.S. clinical trial launch in second half of 2026 Peer-Reviewed Studies published in The Journal of Diabetes Research and in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support advancement of Company's implantable CBGM technology Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercializat
- SECGlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring TechnologyRUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has submitted its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a US clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The IDE submission represents an important step for Glucotrack and reflects the Company's progress to date in its preclinical development and technical foundation of the technology. With this su
- SECSEC Form EFFECT filed by GlucoTrack Inc.EFFECT - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring TechnologyRUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model. The study, titled "In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack™ Inc. Investigation," (Tapsak, M. A.
- SECSEC Form POS AM filed by GlucoTrack Inc.POS AM - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring TechnologyRUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer-reviewed scientific article in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal characterizing the long-term in-vitro stability of electrochemical glucose sensors of the type used in the Company's fully implantable continuous blood glucose monitoring (CBGM) system. The findings represent the first year-long measurement of glucose oxidase enzyme decay reported in the literat
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form 10-K filed by GlucoTrack Inc.10-K - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsCompany prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack's implantablecontinuous blood glucose monitoring (CBGM) technology, strengthening the Company'sintellectual property portfolio Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year
- SECGlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 MilestonesRUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during Q2 of 2026. "In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring tec
- SECGlucoTrack Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack to Present at LSI USA '26 Medtech Innovation SummitRUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California. The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack's continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization
- SECSEC Form DEF 14A filed by GlucoTrack Inc.DEF 14A - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form PRE 14A filed by GlucoTrack Inc.PRE 14A - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM PlatformRUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood glucose monitoring (CBGM) platform. The patents strengthen Glucotrack's competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. The three patents protect key technologies in Glucotra
- SECSEC Form EFFECT filed by GlucoTrack Inc.EFFECT - Glucotrack, Inc. (0001506983) (Filer)
GCTK FAQ
5 questionsWhat does GlucoTrack Inc. do?
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Where does GCTK stock trade?
GlucoTrack Inc. (GCTK) is listed on NASDAQ.What sector and industry is GCTK in?
GlucoTrack Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to GCTK?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare GCTK side-by-side with any of them on Quantisnow.How can I track GCTK on Quantisnow?
Quantisnow aggregates GlucoTrack Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GCTK to receive live email and push alerts on every new disclosure.